Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo solution Clear all
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566
View directory record Official record
Conditions
Postoperative Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

NCT03453541
View directory record Official record
Conditions
Analgesic Adverse Reaction
Interventions
Ketorolac Tromethamine, 0.9% Normal Saline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Years to 18 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337
View directory record Official record
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

NCT05732194
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-333, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

NCT00371137
View directory record Official record
Conditions
Fibromyalgia
Interventions
Xyrem®, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Anniston, Alabama • Huntsville, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional

Ketamine for OUD and Suicidal Ideation in the ED

NCT06111339
View directory record Official record
Conditions
Opioid Use Disorder, Suicidal Ideation
Interventions
Ketamine, Saline Solution
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Not listed Not applicable Interventional

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

NCT02379689
View directory record Official record
Conditions
Degenerative Disc Disease, Pain
Interventions
Injectable placental tissue extract called BioDGenesis (Active Product), Placebo
Drug
Lead sponsor
Semmes-Murphey Foundation
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Puyallup, Washington, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Perio. Maint. With Diode LBR

NCT05276817
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
Epic Diode, HP, Sham
Device · Drug
Lead sponsor
Biolase Inc
Industry
Eligibility
30 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

NCT03928496
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
AbobotulinumtoxinA, Normal saline
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 17, 2026, 4:55 AM EDT
Withdrawn Not applicable Interventional

Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms

NCT05892276
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Trauma Memory Reactivation, Cannabidiol (CBD) Broad-Spectrum Oil, Placebo Oil
Behavioral · Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

NCT05163223
View directory record Official record
Conditions
Breast Cancer
Interventions
AST-301(pNGVL3-hICD), rhuGM-CSF, Placebo, Pembrolizumab, Capecitabine
Biological · Drug
Lead sponsor
Aston Sci. Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Chandler, Arizona • La Jolla, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Results available

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

NCT02239562
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
sPIF, Placebo
Drug
Lead sponsor
Christopher O'Brien, MD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 4:55 AM EDT